AcelRx Pharmaceuticals Inc - SIC # 2834 - PHARMACEUTICAL PREPARATIONS

Ticker Exchange SIC # Website Latest Ticker
ACRX Nasdaq 2834 http://www.acelrx.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for AcelRx Pharmaceuticals Inc

AcelRx Pharmaceuticals (ACRX) Reports Q4 Loss, Lags Revenue Estimates - Mar 30th, 2023 10:15 pm
AcelRx Pharmaceuticals Reports Full Year and Fourth Quarter 2022 Financial Results and Provides Corporate Update - Mar 30th, 2023 8:05 pm
12 Cheap Healthcare Stocks to Buy in 2023 - Mar 29th, 2023 2:13 pm
AcelRx to Host Full Year and Fourth Quarter 2022 Financial Results Call and Webcast on March 30, 2023 - Mar 21st, 2023 8:05 pm
AcelRx Pharmaceuticals Announces Divestment of DSUVIA® to Alora Pharmaceuticals - Mar 14th, 2023 12:30 pm
AcelRx Pharmaceuticals Announces Peer-Reviewed Publication On the Use of DSUVIA® For In-Office Rhinology Procedures - Mar 1st, 2023 1:30 pm
AcelRx Pharmaceuticals, Inc. (NASDAQ:ACRX) Q3 2022 Earnings Call Transcript - Dec 29th, 2022 11:02 am
AcelRx Announces $7.5 Million Registered Direct Offering of Common Stock and Warrants to Purchase Common Stock - Dec 27th, 2022 1:30 pm
10 Cheapest Stocks With Biggest Upside - Dec 19th, 2022 1:17 pm
AcelRx Pharmaceuticals Announces European Peer-Reviewed Publication Supporting the Benefits of Sublingual Sufentanil Tablets For Post-Operative Pain Management in the Journal of Clinical Medicine - Dec 8th, 2022 1:30 pm
AcelRx Pharmaceuticals Third Quarter 2022 Earnings: EPS Beats Expectations, Revenues Lag - Nov 17th, 2022 10:17 am
AcelRx Pharmaceuticals (ACRX) Reports Q3 Loss, Misses Revenue Estimates - Nov 14th, 2022 10:15 pm
AcelRx Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Corporate Update - Nov 14th, 2022 9:01 pm
AcelRx to Host Third Quarter 2022 Financial Results Call and Webcast on November 14, 2022 - Nov 3rd, 2022 12:30 pm
AcelRx Pharmaceuticals Announces Presentation of a Large Cohort of Complex Plastic Surgery Procedures Performed with DSUVIA at Plastic Surgery The Meeting 2022 - Oct 31st, 2022 12:30 pm
AcelRx Pharmaceuticals Announces the European Launch of DZUVEO by its Partner, Aguettant - Oct 27th, 2022 12:30 pm
AcelRx Pharmaceuticals Announces Presentation of Investigator-Initiated Trial Results Comparing AcelRx's Sufentanil Sublingual Tablet (SST) Versus Intravenous Opioids for Postoperative Pain at the ANESTHESIOLOGY® Annual Meeting 2022 - Oct 26th, 2022 12:30 pm
AcelRx Pharmaceuticals Announces Reverse Stock Split - Oct 25th, 2022 8:42 pm
AcelRx Pharmaceuticals Announces ANESTHESIOLOGY® 2022 Annual Meeting Presentation on DSUVIA® for Battlefield Analgesia by the Uniformed Services University of the Health Sciences - Oct 25th, 2022 12:30 pm
AcelRx Pharmaceuticals to Participate in the H.C. Wainwright Annual Investment Conference - Sep 6th, 2022 8:30 pm